- AstraZeneca could pay up to $6 billion to Japan's Daiichi Sankyo to develop and market a type of targeted cancer treatment in the second multi-billion dollar cancer drug collaboration between the two companies.
The drugmakers signed a near $7 billion deal last year for a breast cancer treatment, now called Enhertu, which is being tested in other tumour types too.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
US doubles spending on potential coronavirus vaccine to nearly US$1 billionWASHINGTON (AFP) - The United States has doubled its investment - to nearly US$1 billion (S$1.38 billion) - to expedite development of a potential Covid-19 vaccine by American firm Moderna, which on Monday (July 27) begins the decisive final phase of clinical trials.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »
US doubles spending on potential virus vaccine to nearly US$1 billionThe United States has doubled its investment - to nearly US$1 billion - to expedite development of a potential COVID-19 vaccine by American firm ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
US doubles spending on potential virus vaccine to nearly US$1 billionThe United States has doubled its investment - to nearly US$1 billion - to expedite development of a potential COVID-19 vaccine by American firm ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
SAP to float Qualtrics, partly unwinding US$8 billion buyBusiness software group SAP said on Sunday it planned to float Qualtrics, the U.S. specialist in measuring online customer sentiment, which it ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »